tazarotene has been researched along with halobetasol in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.25) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 17 (53.13) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Hecker, D; Lebwohl, M; Worsley, J; Yueh, G | 1 |
| Alexander, BJ; Gold, LS; Lebwohl, MG; Pariser, DM; Pillai, R; Sugarman, JL | 1 |
| Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL | 1 |
| Green, LJ; Lin, T; Pariser, DM; Pillai, R; Stein Gold, L; Sugarman, JL | 1 |
| Bagel, J; Israel, R; Lin, T; Martin, G; Pillai, R; Stein Gold, L; Sugarman, JL; Tanghetti, EA; Weiss, J; Yamauchi, PS | 1 |
| Kang, R; Kircik, LH; Lin, T; Pariser, D; Pillai, R; Stein Gold, L; Sugarman, JL | 1 |
| Gold, LS; Harris, S; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Sugarman, JL | 1 |
| Bagel, J; Lebwohl, M; Lin, T; Martin, G; Pillai, R; Stein Gold, L | 1 |
| Harris, S; Kircik, LH; Papp, KA; Pharm, TL; Pillai, R; Stein Gold, L | 1 |
| Blauvelt, A; Green, LJ; Lebwohl, MG; Lin, T; Martin, G; Pillai, R; Yamauchi, PS | 1 |
| Evans, EL; Radonjic, A | 1 |
| Angel, A; Del Rosso, JQ; Lin, T; Pillai, R; Stein Gold, L; Tanghetti, EA | 1 |
| Israel, R; Lebwohl, MG; Lin, T; Stein Gold, L; Sugarman, JL | 1 |
| Arcara, A; Benfield, M; Brown, J; Crump, LH; Mospan, C; Mospan, G; Ramey, C; Yang, S | 1 |
| Jacobson, A; Kircik, LH; Lin, T; Tyring, S; Yamauchi, P | 1 |
| Draelos, Z; Elewski, B; Jacobson, A; Lin, T; Stein Gold, L | 1 |
| Alexis, AF; Desai, SR; Jacobson, A | 1 |
| Hansen, JB; Nyholm, N; Patel, DS; Swensen, AR; Veverka, KA; Wu, JJ | 1 |
| Ayyagari, R; Glick, B; Guerin, A; Jacobson, A; Joseph, G; Kircik, L; Lin, T | 1 |
| Han, G; Harris, S; Jacobson, A; Lebwohl, MG; Lin, T; Papp, K; Pariser, DM; Stein Gold, L | 1 |
| Friedman, A; Hou, A; Shoen, E; Zahn, J | 1 |
| Alexis, AF; Desai, SR; Han, G; Jacobson, A | 1 |
| Bhatia, N; Drew, S; Jacobson, A; Tanghetti, EA | 1 |
| Kircik, L; Ozyurekoglu, E | 1 |
| Guenther, L; Metelitsa, A; Prajapati, VH | 1 |
| Bagel, J; Nelson, E; Novak, K | 1 |
| Issa, N; Kircik, L | 1 |
| Babalola, F; Campbell, C; Gottlieb, A; Mitchell, K; Vargas, J; Yousif, J | 1 |
| Armstrong, A; Del Rosso, J; Han, G; Jacobson, A; Lewitt, GM | 1 |
| Bhatia, N; Jacobson, A; Kircik, L; Lain, E | 1 |
3 review(s) available for tazarotene and halobetasol
| Article | Year |
|---|---|
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Topics: Clinical Trials, Phase III as Topic; Clobetasol; Dermatitis; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Multicenter Studies as Topic; Nicotinic Acids; Pain; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Skin Cream; Treatment Outcome | 2018 |
Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion.
Topics: Clobetasol; Dermatologic Agents; Drug Combinations; Emollients; Emulsions; Humans; Motivation; Nicotinic Acids; Psoriasis; Quality of Life; Severity of Illness Index; Skin Cream; Treatment Outcome | 2023 |
Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene.
Topics: Excipients; Humans; Propionates; Psoriasis; Steroids | 2023 |
14 trial(s) available for tazarotene and halobetasol
| Article | Year |
|---|---|
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Glucocorticoids; Humans; Male; Nicotinic Acids; Pharmaceutical Vehicles; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2017 |
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Topics: Administration, Cutaneous; Chronic Disease; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Drug Synergism; Female; Humans; Male; Middle Aged; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2018 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Drug Synergism; Humans; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2018 |
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Drug Compounding; Humans; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Time Factors; Treatment Outcome; Vasoconstrictor Agents | 2018 |
Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.
Topics: Adult; Aged; Aged, 80 and over; Clobetasol; Dermatologic Agents; Drug Therapy, Combination; Humans; Middle Aged; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Time Factors; Young Adult | 2019 |
Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Emulsions; Humans; Nicotinic Acids; Psoriasis; Severity of Illness Index; Treatment Outcome | 2018 |
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Drug Synergism; Follow-Up Studies; Humans; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2019 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Follow-Up Studies; Humans; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2019 |
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
Topics: Adult; Clobetasol; Dermatitis, Contact; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Nicotinic Acids; Pain; Pruritus; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2019 |
Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Leg; Male; Middle Aged; Nicotinic Acids; Psoriasis; Severity of Illness Index; Treatment Outcome; United States | 2020 |
Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Topics: Adult; Aged; Clobetasol; Dermatitis, Contact; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Nicotinic Acids; Pain; Pruritus; Psoriasis; Severity of Illness Index; Sex Factors; Skin Cream; Treatment Outcome | 2020 |
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; Nicotinic Acids; Propionates; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2021 |
Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color.
Topics: Adult; Clobetasol; Color; Dermatologic Agents; Drug Combinations; Humans; Nicotinic Acids; Psoriasis; Skin Cream; Skin Pigmentation | 2021 |
Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
Topics: Body Surface Area; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; Nicotinic Acids; Propionates; Psoriasis; Quality of Life; Severity of Illness Index; Skin Cream; Treatment Outcome | 2021 |
15 other study(ies) available for tazarotene and halobetasol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Evaluation, Preclinical; Drug Incompatibility; Fluocinonide; In Vitro Techniques; Mometasone Furoate; Nicotinic Acids; Pregnadienediols; Psoriasis | 2000 |
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
Topics: Administration, Cutaneous; Clinical Trials, Phase III as Topic; Clobetasol; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Humans; Multicenter Studies as Topic; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2019 |
A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis.
Topics: Administration, Cutaneous; Clobetasol; Dermatologic Agents; Drug Combinations; Humans; Nicotinic Acids; Psoriasis | 2019 |
Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
Topics: Clobetasol; Dermatologic Agents; Drug Combinations; Emulsions; Humans; Nicotinic Acids; Psoriasis; Severity of Illness Index; Treatment Outcome | 2021 |
Drug updates and approvals: 2019 in review.
Topics: Antibodies, Monoclonal; Azetidines; Benzyl Compounds; beta-Cyclodextrins; Carbamates; Clobetasol; Drug Approval; Drug Combinations; Formoterol Fumarate; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Nicotinic Acids; Oxazines; Phenylalanine; Piperazines; Pregnanolone; Pyridones; Tropanes; United States; United States Food and Drug Administration | 2019 |
Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report
Topics: Administration, Cutaneous; Black or African American; Clobetasol; Drug Combinations; Esthetics; Humans; Hypopigmentation; Male; Middle Aged; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Skin Pigmentation; Treatment Outcome | 2020 |
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matchi
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adju
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Successful Treatment of Lichen Amyloidosis Using a Fixed Combination of Halobetasol-Propionate and Tazarotene Lotion.
Topics: Amyloidosis; Biopsy; Clobetasol; Drug Combinations; Humans; Male; Middle Aged; Nicotinic Acids; Skin; Skin Cream; Treatment Outcome | 2021 |
An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis.
Topics: Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Humans; Nicotinic Acids; Pilot Projects; Psoriasis; Quality of Life; Scalp; Severity of Illness Index; Skin Cream; Treatment Outcome | 2021 |
Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.
Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatologic Agents; Drug Combinations; Humans; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream | 2021 |
Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis.
Topics: Administration, Cutaneous; Adult; Biological Products; Clobetasol; Dermatologic Agents; Drug Combinations; Emollients; Humans; Nicotinic Acids; Propionates; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome | 2022 |
Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations.
Topics: Administration, Cutaneous; Dermatologic Agents; Drug Combinations; Emollients; Emulsions; Endothelial Cells; Humans; Nicotinic Acids; Psoriasis; Retinoids; Severity of Illness Index; Skin Cream; Treatment Outcome | 2023 |
An Investigator-Initiated Trial of a Polymeric Emulsion of Halobetasol Propionate and Tazarotene in the Treatment of Palmoplantar Psoriasis.
Topics: Adult; Clobetasol; Dermatologic Agents; Double-Blind Method; Drug Combinations; Emulsions; Humans; Nicotinic Acids; Psoriasis; Quality of Life; Severity of Illness Index; Skin Cream; Treatment Outcome | 2023 |